Nonsteroidal anti-inflammatory drug-induced fracture nonunion: An inhibition of angiogenesis?

Journal of Bone and Joint Surgery

Volumn 88, Issue SUPPL. 3, 2006, Pages 140-147

  Murnaghan, Mark ^a   Li, Gang ^b   Marsh, David R ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHYLCELLULOSE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD FLOWMETRY; BONE RADIOGRAPHY; CHEMICAL ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMUR FRACTURE; FRACTURE NONUNION; HISTOPATHOLOGY; INHIBITION KINETICS; LASER DOPPLER FLOWMETRY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WOUND HEALING;

EID: 33750697333     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.F.00454     Document Type: Conference Paper

References (43)

1. Carano RA, Filvaroff EH. Angiogenesis and bone repair. Drug Discov Today. 2003;8:980-9.
2. Bo J, Sudmann E, Marton PF. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand. 1976;47:588-99.
3. Martin GJ Jr, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine. 1999;24:2188-94.
4. Long J, Lewis S, Kuklo T, Zhu Y, Riew KD. The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am. 2002;84:1763-8.
5. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res. 2002;20:1164-9.
6. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res. 2002;17:963-76.
7. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405-15.
8. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000;82:655-8.
9. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk, of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700-5.
10. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine. 1998;23:834-8.
11. Murnaghan JM, Marsh DR. NSAID use following skeletal trauma. Br J Gen Pract. 2003;53:407-8.
12. Harada SI, Balena R, Rodan GA, Rodan SB. The role of prostaglandins in bone formation. Connect Tissue Res. 1995;31:279-82.
13. Mori S, Jee WS, Li XJ, Chan S, Kimmel DB. Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of ovariectomized rats. Bone. 1990;11:103-13.
14. Li XJ, Jee WS, Li YL, Patterson-Buckendahl P. Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs. Bone. 1990;11:353-64.
15. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149-58.
16. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res. 1995;313:36-46.
17. Jee WS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. Bone. 1997;21:297-304.
18. Fendrick AM. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care. Am J Manag Care. 2002;8(17 Suppl):S529-41.
19. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-66.
20. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342:1960-8.
21. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029-34.
22. int' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-21.
23. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-16.
24. Erratum in: Cell. 1998;94:following 271.
25. Jones MK, Wang H, Peskar BM, Levin E, ltani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-23.
26. von Haller A. Experimentorum de ossiem formatione. In: Opera minora: emendata, aucta, et renovata. Lausanne: François Grasset: 1762-8. p 400.
27. Connolly CK, Li G, Bunn JR, Mushipe M, Dickson GR, Marsh DR. A reliable externally fixated murine femoral fracture model that accounts for variation in movement between animals. J Orthop Res. 2003;21:843-9.
28. United States Food and Drug Administration, Center for Drug Evaluation and Research. Dose calculator. www.fda.gov/cder/cancer/animalframe.htm.
29. Connolly C. The effects of the preferential COX-2 inhibitor, meloxicam and motion on fracture healing. [PhD dissertation]. Belfast: Queen's University Belfast; 2001. p 265.
30. Pufe T, Wildemann B, Petersen W, Mentlein R, Raschke M, Schmidmaier G. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res. 2002;309:387-92.
31. Uchida S, Sakai A, Kudo H, Otomo H, Watanuki M, Tanaka M, Nagashima M, Nakamura T. Vascular endothelial growth factor is expressed along with its receptors during the healing process of bone and bone marrow after drill-hole injury in rats. Bone. 2003;32:491-501.
32. Keast-Butler O, Shenava Y, Rajaratnam S, Phillips S, Groom G, Goss D. In vivo measurement of tibial blood flow during distraction osteogenesis using Doppler ultrasonography. Read at the ARCO/ISFR Combined Symposium; 2005 Sept 15-17; London, UK.
33. Trueta J, Morgan JD. The vascular contribution to osteogenesis. I. Studies by the injection method. J Bone Joint Surg Br. 1960;42:97-109.
34. Winet H. The role of microvasculature in normal and perturbed bone healing as revealed by intravital microscopy. Bone. 1996;19(1 Suppl):39S-57S.
35. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999;134:1325-32.
36. Clauss M, Sunderkotter C, Sveinbjornsson B, Hippenstiel S, Willuweit A, Marino M, Haas E, Seljelid R, Scheurich P, Suttorp N, Grell M, Risau W. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood. 2001;97:1321-9.
37. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998;111:1-6.
38. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood. 1997;90:4153-61.
39. Garcia-Vicuna R, Diaz-Gonzalez F, Gonzalez-Alvaro I, del Pozo MA, Mollinedo F, Cabanas C, Gonzalez-Amaro R, Sanchez-Madrid F. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum. 1997;40:143-53.
40. Shirley D, Marsh D, Jordan G, McQuaid S, Li G. Systemic recruitment of osteoblastic cells in fracture healing. J Orthop Res. 2005;23:1013-21.
41. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Cruceta J, Graves BD, Einhorn TA. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs. 2001;169:285-94.
42. Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B, Cullinane D, Einhorn TA. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res. 2003;21:670-5.
43. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res. 2001;19:785-96.